Alnylam’s Amvuttra To Take Off From Onpattro’s Runway
Most Onpattro Patients Expected To Switch
The company won approval in hATTR amyloidosis polyneuropathy for the RNAi drug, which offers quarterly subcutaneous dosing versus Onpattro’s I.V. administration every three weeks.
You may also be interested in...
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The company announced a respectable increase in second quarter sales and expects to announce topline results within the next three weeks for the Phase III trial of Onpattro in ATTR-CM.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.